Bharat Biotech
-
The biopolitics of Covaxin
In a new investigation, STAT has reported fresh problems with Covaxin’s approval process in India, including the phase 2 trial dropping its placebo arm in favour of one preordained to make Covaxin look good and Bharat Biotech – the maker – commencing phase 3 trials based on results from animal studies. I’m also filing the report… Continue reading
-
About vaccines for children and Covaxin…
I don’t understand his penchant for late-night announcements, much less one at 10 pm on Christmas night, but Prime Minister Narendra has just said the government will roll out vaccines for young adults aged 15-18 years from January 3, 2022 – around the same time I received a press release from Bharat Biotech saying the… Continue reading
-
The toxic affair between Covaxin and The Lancet
That Covaxin has been leading a ceaselessly beleaguered life is no mystery – but The Lancet journal may not know that it has been pressed into the questionable service of saving the vaccine’s reputation on at least three occasions. In the latest one, for example, Bharat Biotech, some clueless media outlets and their hordes of… Continue reading
-
Is Covaxin’s WHO approval guaranteed?
I suspect after reading this PTI report that the WHO is practically helping Bharat Biotech put together a better application to have its COVID-19 vaccine, Covaxin, get the body’s approval for international use, instead of simply considering what Bharat Biotech chooses to submit. The overall tone of the report is mollificatory – as if the… Continue reading
-
It’s great that the WHO isn’t just ‘not cutting corners’
Call me anti-national (and I’m sure many will) but I’m glad that the WHO isn’t just “not cutting corners” in the process of considering Bharat Biotech’s application for the UN body’s stamp of approval Covaxin but is also openly calling for more and more information from the company at periodic intervals. This isn’t just a… Continue reading
-
Bharat Biotech gets 1/10 for tweet
If I had been Bharat Biotech’s teacher and “Where is your data?” had been an examination question, Bharat Biotech would have received 1 out of 10 marks. The correct answer to where is your data can take one of two forms: either an update in the form of where the data is in the data-processing… Continue reading
-
India’s missing research papers
If you’re looking for a quantification (although you shouldn’t) of the extent to which science is being conducted by press releases in India at the moment, consider the following list of studies. The papers for none of them have been published – as preprints or ‘post-prints’ – even as the people behind them, including many… Continue reading
Bharat Biotech, Biocon, Covaxin, COVID-19, COVID-19 epidemic, COVID-19 pandemic, ELISA test kit, favipiravir, hydroxychloroquine, Indian Council of Medical Research, Itolizumab, novel coronavirus, peer review, preprint papers, remdesivir, science academies, science by press release, seroprevalence survey, Tata Institute of Fundamental Research, tocilizumab, Zydus Cadila
About Me
I’m a science editor and writer in India, interested in high-energy and condensed-matter physics, research misconduct, pseudoscience, science’s relationship with society, epic fantasy, open source/access/knowledge systems, H.R. Giger’s art, Goundamani’s comedy, Factorio, and most things that require a lot of time to get the hang of.